Status:

COMPLETED

Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Lead Sponsor:

Amgen

Conditions:

Lung Cancer

Non-Small Cell Lung Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

The purpose of this trial is: - To characterize the safety profile of motesanib when used in combination with carboplatin/paclitaxel (CP), with panitumumab or with CP and panitumumab in patients with ...

Detailed Description

This was a multicenter, open-label, dose-finding clinical trial examining the safety and PK of once or twice daily motesanib administered with CP or with CP and panitumumab in chemotherapy naïve patie...

Eligibility Criteria

Inclusion

  • Diagnosis of unresectable stage IIIB or IV non-small cell lung cancer (NSCLC)
  • No more than one prior chemotherapy
  • Adequate hematologic, renal and hepatic function
  • Measurable disease or evaluable disease on CAT scan or MRI
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Able to fast for 10 hrs twice during the study - Able to tolerate oral medications
  • Life expectancy of at least 3 months

Exclusion

  • Symptomatic or untreated central nervous system metastases requiring current treatment
  • History of arterial thrombosis within 1 year prior to enrollment
  • Anticoagulant therapy, except for warfarin of less than 2mg per day
  • Symptomatic peripheral neuropathy
  • History of pulmonary hemorrhage or hemoptysis
  • Myocardial infarction within 1 year before enrollment
  • Uncontrolled hypertension \[diastolic greater than 85 mmHg; systolic greater than 145 mmHg\]
  • History of other cancer, unless treated with no known active disease for longer than 3 years
  • Previous treatment with AMG 706 or panitumumab, previous treatment with inhibitors of VEGF or EGF
  • No antibody treatment for 6 weeks prior to enrollment
  • Known HIV positive, hepatitis C positive or hepatitis B surface antigen positive

Key Trial Info

Start Date :

January 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2007

Estimated Enrollment :

51 Patients enrolled

Trial Details

Trial ID

NCT00094835

Start Date

January 1 2005

End Date

March 1 2007

Last Update

March 24 2016

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.